DEF: X4 Pharmaceuticals Proposes Reverse Stock Split to Regain Nasdaq Compliance

X4 Pharmaceuticals is seeking stockholder approval for a reverse stock split to meet Nasdaq's minimum bid price requirement and potentially attract a broader range of investors.

Summary

• X4 Pharmaceuticals is holding a special meeting on April 17, 2025, to vote on a proposal to amend its Restated Certificate of Incorporation to enact a reverse stock split.
• The proposed reverse stock split would combine outstanding shares of common stock at a ratio between 1-for-15 and 1-for-30, with the exact ratio determined by the Board of Directors.
• The primary reason for the reverse stock split is to increase the per-share trading price of the common stock to meet Nasdaq's listing requirements, which mandate a minimum bid price of $1.00 per share.
• As of March 13, 2025, the closing bid price for X4 Pharmaceuticals' common stock on Nasdaq was $0.32 per share.
• The company received a deficiency letter from Nasdaq on August 13, 2024, for not maintaining the minimum required closing bid price.
• Nasdaq granted the company an additional 180-day compliance period, until August 11, 2025, to regain compliance.
• Failure to approve the reverse stock split could result in the delisting of the company's common stock from Nasdaq.
• The Board of Directors believes that a higher stock price may attract a broader range of investors, including institutional investors and brokerage firms that may be reluctant to recommend lower-priced securities.
• The reverse stock split would reduce the number of outstanding shares of common stock without reducing the number of authorized shares, potentially increasing the number of shares available for future issuance.
• As of the record date, there were 173,662,376 shares of common stock outstanding.
• The company is also seeking approval to adjourn the special meeting, if necessary, to solicit additional proxies if there are insufficient votes in favor of the reverse stock split proposal.
• The Board of Directors reserves the right to abandon the reverse stock split if it determines it is no longer in the company's best interest.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. While the reverse stock split is presented as a necessary step to maintain Nasdaq listing, it also acknowledges the risks and potential negative perceptions associated with such actions. The company expresses hope for attracting a broader range of investors, but there's no guarantee of success.

Positives

• A successful reverse stock split could help the company regain compliance with Nasdaq listing requirements.
• A higher stock price may attract a broader range of investors, including institutional investors.
• The reverse stock split could improve the perception of the company's common stock as a viable investment security.
• The Board has the flexibility to set the exact reverse split ratio within the approved range to maximize benefits.
• The company has been granted an additional compliance period by Nasdaq until August 11, 2025.

Negatives

• The reverse stock split may not result in an increase in the per-share price of the common stock.
• The reverse stock split could reduce the liquidity of the company's common stock.
• Some investors may have a negative perception of reverse stock splits.
• The market price of the common stock will also be based on the performance of the company and other factors.
• The reverse stock split could increase the proportion of unissued authorized shares to issued shares, which could have possible anti-takeover effects.

Risks

• The reverse stock split may not increase the market price of the common stock.
• The company may not meet the listing requirements even after the reverse stock split.
• The market price of the common stock could decline after the reverse stock split.
• The reverse stock split could reduce the number of outstanding shares, potentially impairing liquidity.
• The increased proportion of unissued authorized shares could have anti-takeover effects.

Future Outlook

The company aims to regain compliance with Nasdaq listing requirements through the reverse stock split and potentially attract a broader range of investors. The company is exploring various sources of financing, including through potential future sales of Common Stock or other securities. There can be no assurance, however, even if the Reverse Stock Split is approved and implemented, that any financing transaction would be undertaken or completed. If we are unable to successfully raise sufficient additional capital, through future sales of Common Stock or other securities or through strategic and collaborative arrangements, we will not have sufficient cash to fund our planned business operations and or may not be able to continue as a going concern.

Management Comments

• The Board strongly believes that the Reverse Stock Split is necessary to maintain our listing on Nasdaq.
• The Board recommended that our shareholders approve the Reverse Stock Split Proposal to effect the Reverse Stock Split and directed that this proposal be submitted to our shareholders for approval at the Special Meeting.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices. Many companies in the biotechnology and pharmaceutical industries, particularly those in the development stage, may face similar challenges in maintaining compliance with listing requirements.

Comparison to Industry Standards

• Many companies facing similar situations, such as delisting warnings from Nasdaq or NYSE, have implemented reverse stock splits.
• For example, companies like BioDelivery Sciences International and Titan Pharmaceuticals have used reverse stock splits to regain compliance with Nasdaq's minimum bid price rule.
• The success of a reverse stock split in maintaining listing and improving stock price varies depending on the company's underlying financial health and market conditions.
• Some companies have successfully maintained their listing and seen a temporary increase in stock price, while others have continued to struggle despite the reverse stock split.

Stakeholder Impact

• Shareholders: The reverse stock split will affect the number of shares they own and potentially the value of their investment.
• Employees: The company's ability to maintain its Nasdaq listing could impact employee morale and stock options.
• Investors: The reverse stock split aims to attract a broader range of investors, potentially increasing demand for the company's stock.

Next Steps

• Stockholder vote on the reverse stock split proposal at the Special Meeting on April 17, 2025.
• Board of Directors' decision on whether to implement the reverse stock split and the specific ratio within the approved range.
• Filing of the Certificate of Amendment with the Delaware Secretary of State if the reverse stock split is approved and implemented.
• Potential future sales of Common Stock or other securities to raise additional capital.

Key Dates

Keywords

reverse stock split, Nasdaq, compliance, common stock, listing requirements, stock price, investors, proxy statement, X4 Pharmaceuticals